Antisense compounds, compositions and methods are provided for modulating the expression of Phosphorylase kinase alpha 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phosphorylase kinase alpha 1. Methods of using these compounds for modulation of Phosphorylase kinase alpha 1 expression and for treatment of diseases associated with expression of Phosphorylase kinase alpha 1 are provided.
Claims What is claimed is: 1. A antisense compound 8 to 50 nucleobases in length targeted to a start codon region, a coding region, a stop codon region, or a 3'-untranslated region of human Phosphorylase kinase alpha 1 (SEQ ID NO: 3) or a coding region of mouse Phosphorylase kinase alpha 1 (SEQ ID NO: 10) or a coding region of rat Phosphorylase kinase alpha 1 (SEQ ID NO: 17), wherein said antisense compound specifically hybridizes with one of said regions and inhibits the expression of Phosphorylase kinase alpha 1. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine. 9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 11. The composition of claim 10 further comprising a colloidal dispersion system. 12. The composition of claim 10 wherein the compound is an antisense oligonucleotide. 13. A method of inhibiting the expression of Phosphorylase kinase alpha 1 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of Phosphorylase kinase alpha 1 is inhibited. 14. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 103, 104, 105, 106, 107, 108, 109, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177 or 178 which inhibits the expression of Phosphorylase kinase alpha 1. 15. The antisense compound of claim 14 which is an antisense oligonucleotide. 16. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The antisense compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The antisense compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The antisense compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The antisense compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A method of inhibiting the expression of Phosphorylase kinase alpha 1 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 14 so that expression of Phosphorylase kinase alpha 1 is inhibited. 24. A composition comprising the antisense compound of claim 14 and a pharmaceutically acceptable carrier or diluent. 25. The composition of claim 24 further comprising a colloidal dispersion system. 26. The composition of claim 24 wherein the antisense compound is an antisense oligonucleotide. 